Shionogi, Sage to Partner on Developing Depression Drug in Three Asian Markets

Shionogi & Co. will partner with Sage Therapeutics to develop and commercialize Sage’s SAGE-217 to treat major depressive disorder (MDD) and other indications in Japan, Taiwan, and South Korea, through a collaboration that could generate up to $575 million-plus for Sage.The companies said their collaboration is aimed at speeding up development in key Asian markets for SAGE-217.Shionogi and Sage disclosed their Asian collaboration last night, a day after Sage announced plans to launch a